Kaplan–Meier curves depicting overall survival (OS; a, b) and... | Download Scientific Diagram
Individualized therapy for metastatic renal cell carcinoma
Cancers | Free Full-Text | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Cureus | Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma? | Article
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine
Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram
JCM | Free Full-Text | Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
Determinants of renal cell carcinoma invasion and metastatic competence | Nature Communications
Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram
Frontiers | Causes of Death and Conditional Survival of Renal Cell Carcinoma
Five-year overall survival curves of renal cell carcinoma patients... | Download Scientific Diagram
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program | Journal for ImmunoTherapy of Cancer
Frontiers | Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry | Future Oncology
Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
Overall survival rates of 95 patients with metastatic renal cell... | Download Scientific Diagram
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints
xmlinkhub
Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study - European Urology Focus
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma | NEJM
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
